Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Chief Medical Officer | February 17, 2021 | February 19, 2021 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Chief Medical Officer | January 25, 2019 | January 30, 2019 |
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | March 24, 2026 | March 25, 2026 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | October 21, 2021 | October 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date February 17, 2021 · Filed February 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.69 · Expires 2031-02-16 | Direct | 60,000 |
Reported balance
After 2021-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-17 · Grant · Acquired 60,000 · Balance 60,000 F1: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
CytomX Therapeutics, Inc.
Report date January 25, 2019 · Filed January 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.85 · Expires 2029-01-24 | Direct | 90,000 |
Reported balance
After 2019-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-25 · Grant · Acquired 90,000 · Balance 90,000 F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Pyxis Oncology, Inc.
Report date March 24, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24 | Direct | 45,867 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Xilio Therapeutics, Inc.
Report date October 21, 2021 · Filed October 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,444 |
Reported balance
Holding disclosure · report date 2021-10-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 9,444 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2030-07-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-10-21 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The option was granted on July 23, 2020 for 14,239 shares. One-third of the shares vested on December 13, 2020, and one third of the shares shall vest on December 13, 2021 and December 13, 2022, respectively. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.89 · Expires 2031-03-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-10-21 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The option was granted on March 11, 2021 for 34,450 shares. On March 11, 2021, 10,048 shares underlying the option vested, with the remainder scheduled to vest in equal monthly installments on the 13th of each month thereafter over the following 34 months. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on July 23, 2020 for 14,239 shares. One-third of the shares vested on December 13, 2020, and one third of the shares shall vest on December 13, 2021 and December 13, 2022, respectively.
F2: The option was granted on March 11, 2021 for 34,450 shares. On March 11, 2021, 10,048 shares underlying the option vested, with the remainder scheduled to vest in equal monthly installments on the 13th of each month thereafter over the following 34 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2026 Filed Mar 25, 2026 17:05 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 45,867 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001193125-26-124319 · ownership.xml · derivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,867 Underlying: Common Stock · 45,867 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| April 21, 2025 Filed Mar 25, 2026 16:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | SaleCommon Stock | 13,896 | $1.03 | $14,361.52 |
DisclosureSEC source: 0000905148-26-001434 · form4.xml · nonDerivative · entry 3 HUMPHREY RACHEL · CIK 0001579781 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,309 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2024. F2 · price: Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 through 4 of this Form 4. F4 · price: The transaction was executed in multiple trades in prices ranging from $0.97 to $1.09. Read SEC document |
| April 17, 2025 Filed Mar 25, 2026 16:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | SaleCommon Stock | 200 | $0.97 | $194.00 |
DisclosureSEC source: 0000905148-26-001434 · form4.xml · nonDerivative · entry 2 HUMPHREY RACHEL · CIK 0001579781 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,205 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2024. Read SEC document |
| April 14, 2025 Filed Mar 25, 2026 16:30 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | SaleCommon Stock | 1,400 | $0.97 | $1,361.78 |
DisclosureSEC source: 0000905148-26-001434 · form4.xml · nonDerivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2024. F2 · price: Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 through 4 of this Form 4. F3 · price: The transaction was executed in multiple trades in prices ranging from $0.97 to $0.98. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 09:03 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 36,979 | $0.98 Strike: $0.98 | $36,239.42 |
DisclosureSEC source: 0000950170-25-048901 · ownership.xml · derivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,979 Underlying: Common Stock · 36,979 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 16:32 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 38,741 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038099 · ownership.xml · nonDerivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,805 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 16:43 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 58,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021408 · doc4.xml · nonDerivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,064 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 17:44 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 236,220 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001140361-22-029677 · form4.xml · derivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,220 Underlying: Common Stock · 236,220 shares Expires 2032-08-11 F1 · derivative.exercise_date: These stock options vest in three equal annual installments from the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:55 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $28.69 | $0.00 |
DisclosureSEC source: 0000899243-21-007440 · doc4.xml · derivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $28.14 | $0.00 |
DisclosureSEC source: 0000899243-20-024836 · doc4.xml · derivative · entry 2 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-09-08 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on September 8, 2021, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 20:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024836 · doc4.xml · nonDerivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three equal annual installments, with the first installment commencing on September 8, 2021, subject to the Reporting Person's continuous service to the Issuer through each vesting date. F1 · balance_after: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three equal annual installments, with the first installment commencing on September 8, 2021, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| January 25, 2019 Filed Jan 30, 2019 00:00 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001567619-19-001865 · doc1.xml · derivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 23:59 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,160 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001140361-18-012113 · doc1.xml · derivative · entry 3 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,980 Underlying: Common Stock · 16,160 shares Expires 2025-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests 25% on August 28, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on August 28, 2019. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 23:59 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 16,160 | $30.00 | $484,800.00 |
DisclosureSEC source: 0001140361-18-012113 · doc1.xml · nonDerivative · entry 2 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,234 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 23:59 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 16,160 | $6.61 | $106,893.55 |
DisclosureSEC source: 0001140361-18-012113 · doc1.xml · nonDerivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,840 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001140361-18-011515 · doc1.xml · derivative · entry 3 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,140 Underlying: Common Stock · 23,840 shares Expires 2025-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests 25% on August 28, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on August 28, 2019. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 23,840 | $30.00 | $715,200.00 |
DisclosureSEC source: 0001140361-18-011515 · doc1.xml · nonDerivative · entry 2 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,234 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 23,840 | $6.61 | $157,694.45 |
DisclosureSEC source: 0001140361-18-011515 · doc1.xml · nonDerivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $25.82 | $0.00 |
DisclosureSEC source: 0001140361-18-003419 · doc1.xml · derivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 17:23 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,117 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001140361-17-046649 · doc1.xml · derivative · entry 2 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,980 Underlying: Common Stock · 15,117 shares Expires 2025-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests 25% on August 28, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on August 28, 2019. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 17:23 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 15,117 | $6.61 | $99,994.42 |
DisclosureSEC source: 0001140361-17-046649 · doc1.xml · nonDerivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001140361-17-003159 · doc1.xml · derivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| December 28, 2016 Filed Dec 29, 2016 20:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,117 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001140361-16-091061 · doc1.xml · derivative · entry 2 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,097 Underlying: Common Stock · 15,117 shares Expires 2025-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests 25% on August 28, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on August 28, 2019. Read SEC document |
| December 28, 2016 Filed Dec 29, 2016 20:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 15,117 | $6.61 | $99,994.42 |
DisclosureSEC source: 0001140361-16-091061 · doc1.xml · nonDerivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.